Similar articles

• Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.

  McClelland HA. McClelland HA. Br J Clin Pharmacol. 1976 Jun;3(3 Suppl 2):401-3. doi: 10.1111/j.1365-2125.1976.tb03733.x. Br J Clin Pharmacol. 1976. PMID: 9966 Free PMC article. Clinical Trial. No abstract available.
• [Aspects of neuroleptic depot therapy with special consideration of clinical experiences with the preoral depot preparation Penfluridol (R 16 341-Jannsen)].

  Bruck J, Guss H. Bruck J, et al. Int Pharmacopsychiatry. 1974;9(3):152-65. Int Pharmacopsychiatry. 1974. PMID: 4154320 German. No abstract available.
• Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.

  Lavin MR, Rifkin A. Lavin MR, et al. J Clin Pharmacol. 1991 Aug;31(8):769-77. doi: 10.1002/j.1552-4604.1991.tb03775.x. J Clin Pharmacol. 1991. PMID: 1679063 Review.
• Sudden dysphagia with uvular enlargement following the initiation of risperidone which responded to benztropine: was this an extrapyramidal side effect?

  Nair S, Saeed O, Shahab H, Sedky K, Garver D, Lippmann S. Nair S, et al. Gen Hosp Psychiatry. 2001 Jul-Aug;23(4):231-2. doi: 10.1016/s0163-8343(01)00145-1. Gen Hosp Psychiatry. 2001. PMID: 11569473 No abstract available.
• Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.

  Murphy JE, Stewart RB. Murphy JE, et al. Am J Hosp Pharm. 1979 May;36(5):641-4. Am J Hosp Pharm. 1979. PMID: 36755 Review.